# SQ3370 from preclinical evaluation to a first-in-human dose-escalation trial: the first click chemistry-based cancer therapeutic

Source: https://onco.cc/key-papers/paper-srinivasan-sq3370-preclinical-to-first-in-human-clin-cancer-res-2025/  
OnCo record `paper-srinivasan-sq3370-preclinical-to-first-in-human-clin-cancer-res-2025` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The paper that reports the first use of click chemistry inside patients. A doxorubicin prodrug switched on at an injected tumour was given at up to 15 times the usual doxorubicin dose without the dose-limiting side effects the trial was watching for.

## Summary

Written by Shasqi scientists with clinical co-authors including the trial's principal investigator, this paper follows SQ3370 from mouse and dog studies into the dose-escalation part of its first trial in people (NCT04106492). SQ3370 is a clickable agent placed at the tumour that reacts with a chemically attenuated doxorubicin and releases the active drug in place.

In mice it slowed tumour growth across several models, releasing doxorubicin in tumours at concentrations the authors say conventional treatment cannot reach. It was given safely at 8.9 times the veterinary doxorubicin dose in dogs and 15 times the conventional dose in patients, with no protocol-defined dose-limiting toxicity. In patients it changed the pharmacokinetics of active doxorubicin and was followed by T-cell-dependent immune responses, including expansion and activation of cytotoxic CD8 T cells in tumours and in the blood.

The abstract reports safety, drug levels and immune changes. It gives no response rate; the efficacy results of the same trial are in a separate preprint.

## Fields

- Kind: Key paper
- Last checked: 2026-11-16
- Also known as: Development of a First-in-Class Click Chemistry-Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
- Journal: Clinical Cancer Research
- Year: 2025
- DOI: 10.1158/1078-0432.CCR-24-2539
- Authors: Srinivasan S, Yee NA, Alečković M, et al.
- Findings: No protocol-defined dose-limiting toxicity in patients at up to 15 times the conventional doxorubicin dose.; Given safely at 8.9 times the veterinary doxorubicin dose in dogs.; Tumour progression was inhibited in several mouse tumour models, with doxorubicin released in tumours at concentrations described as unachievable by conventional treatment.; In patients, cytotoxic CD8 T cells expanded and were activated in tumours and systemically.
- What it means: It establishes that a click reaction between two separately given substances can be run inside a person, and that capping doxorubicin this way lets far more of it be given. It does not establish that patients do better: the abstract reports no tumour responses, and the trial's phase 2a part later found a response rate comparable to standard doxorubicin.
- Caveats: Figures are from the abstract; the full text was not read.; Dose escalation only, with no comparison arm. Company-authored; Europe PMC lists US National Cancer Institute grant R44 CA261573 as support.; An earlier preprint from the same group (bioRxiv, 10.1101/2023.03.28.534654) reported the interim position, 12 times the conventional dose, in March 2023.

## Sources

- Clin Cancer Res 2025: https://doi.org/10.1158/1078-0432.CCR-24-2539
- PubMed: https://pubmed.ncbi.nlm.nih.gov/40522144/
- Europe PMC (free full text): https://europepmc.org/article/MED/40522144
- ClinicalTrials.gov NCT04106492: https://clinicaltrials.gov/study/NCT04106492

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- technologies: [Click-activated prodrugs (bioorthogonal drug activation in the body)](https://onco.cc/technologies/click-activated-prodrugs/)
- drugs: [SQ3370](https://onco.cc/drugs/sq3370/)
- companies: [Shasqi](https://onco.cc/companies/shasqi/)
- trials: [SQ3370 in advanced solid tumours and soft tissue sarcoma (SQ3370-001, phase 1/2a)](https://onco.cc/trials/nct04106492/)
- people: [Sant P. Chawla](https://onco.cc/people/sant-chawla/)
- journals: [Clinical Cancer Research](https://onco.cc/journals/clinical-cancer-research/)

---
JSON: https://onco.cc/api/v1/entities/paper-srinivasan-sq3370-preclinical-to-first-in-human-clin-cancer-res-2025.json